Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
55
NAUT Quote, Financials, Valuation and Earnings
Last price:
$3.31
Seasonality move
:
-13.38%
Day range:
$3.12 - $3.43
52-week range:
$0.62 - $4.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.63x
Volume:
218K
Avg. volume:
335.9K
1-year change:
270.47%
Market cap:
$412.7M
Revenue:
--
EPS (TTM):
-$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
-- | -$0.15 | -- | -- | $4.00 |
|
NAGE
Niagen Bioscience, Inc.
|
$30.4M | $0.06 | -0.82% | 23.36% | $13.60 |
|
NMRA
Neumora Therapeutics, Inc.
|
-- | -$0.31 | -- | -23.34% | $8.91 |
|
PROK
ProKidney Corp.
|
$100.3K | -$0.14 | -56.41% | -7.94% | $6.25 |
|
PYXS
Pyxis Oncology, Inc.
|
-- | -$0.36 | -100% | -4.23% | $6.88 |
|
SIGA
SIGA Technologies, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
$3.31 | $4.00 | $412.7M | -- | $0.00 | 0% | -- |
|
NAGE
Niagen Bioscience, Inc.
|
$4.38 | $13.60 | $350.8M | 21.44x | $0.00 | 0% | 2.88x |
|
NMRA
Neumora Therapeutics, Inc.
|
$2.00 | $8.91 | $348.4M | -- | $0.00 | 0% | -- |
|
PROK
ProKidney Corp.
|
$1.90 | $6.25 | $295.1M | -- | $0.00 | 0% | 284.65x |
|
PYXS
Pyxis Oncology, Inc.
|
$1.48 | $6.88 | $94.3M | -- | $0.00 | 0% | 6.63x |
|
SIGA
SIGA Technologies, Inc.
|
$5.24 | -- | $381.2M | 16.41x | $0.60 | 0% | 4.03x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
16.05% | -3.324 | 12.17% | 13.00x |
|
NAGE
Niagen Bioscience, Inc.
|
3.55% | 3.664 | 0.56% | 3.75x |
|
NMRA
Neumora Therapeutics, Inc.
|
13.19% | 4.059 | 6.81% | 6.64x |
|
PROK
ProKidney Corp.
|
-0.4% | 3.062 | 0.25% | 8.78x |
|
PYXS
Pyxis Oncology, Inc.
|
25.91% | 2.815 | 25.9% | 3.23x |
|
SIGA
SIGA Technologies, Inc.
|
0.4% | 2.342 | 0.34% | 8.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAUT
Nautilus Biotechnology, Inc.
|
-$1.6M | -$15.4M | -27.95% | -32.41% | -- | -$12.6M |
|
NAGE
Niagen Bioscience, Inc.
|
$21.7M | $2.1M | 26.48% | 27.78% | 6.22% | $523K |
|
NMRA
Neumora Therapeutics, Inc.
|
-$23K | -$52.7M | -98.72% | -102.63% | -- | -$46.6M |
|
PROK
ProKidney Corp.
|
-$1.2M | -$45.4M | -43.33% | -43.81% | -20164.89% | -$38.3M |
|
PYXS
Pyxis Oncology, Inc.
|
$5.8M | -$18.3M | -74.98% | -91.8% | -165.75% | -$10.4M |
|
SIGA
SIGA Technologies, Inc.
|
$804.5K | -$9.5M | 11.1% | 11.15% | -250.38% | -$16.9M |
Nautilus Biotechnology, Inc. vs. Competitors
-
Which has Higher Returns NAUT or NAGE?
Niagen Bioscience, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of 12.21%. Nautilus Biotechnology, Inc.'s return on equity of -32.41% beat Niagen Bioscience, Inc.'s return on equity of 27.78%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M NAGENiagen Bioscience, Inc.64.14% $0.05 $79.4M -
What do Analysts Say About NAUT or NAGE?
Nautilus Biotechnology, Inc. has a consensus price target of $4.00, signalling upside risk potential of 21.03%. On the other hand Niagen Bioscience, Inc. has an analysts' consensus of $13.60 which suggests that it could grow by 210.5%. Given that Niagen Bioscience, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 NAGENiagen Bioscience, Inc.5 0 0 -
Is NAUT or NAGE More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Niagen Bioscience, Inc. has a beta of 2.235, suggesting its more volatile than the S&P 500 by 123.522%.
-
Which is a Better Dividend Stock NAUT or NAGE?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Niagen Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Niagen Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or NAGE?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Niagen Bioscience, Inc. quarterly revenues of $33.8M. Nautilus Biotechnology, Inc.'s net income of -$13.8M is lower than Niagen Bioscience, Inc.'s net income of $4.1M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Niagen Bioscience, Inc.'s PE ratio is 21.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 2.88x for Niagen Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M NAGENiagen Bioscience, Inc.2.88x 21.44x $33.8M $4.1M
-
Which has Higher Returns NAUT or NMRA?
Neumora Therapeutics, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of --. Nautilus Biotechnology, Inc.'s return on equity of -32.41% beat Neumora Therapeutics, Inc.'s return on equity of -102.63%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M -
What do Analysts Say About NAUT or NMRA?
Nautilus Biotechnology, Inc. has a consensus price target of $4.00, signalling upside risk potential of 21.03%. On the other hand Neumora Therapeutics, Inc. has an analysts' consensus of $8.91 which suggests that it could grow by 345.38%. Given that Neumora Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 NMRANeumora Therapeutics, Inc.5 1 0 -
Is NAUT or NMRA More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neumora Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAUT or NMRA?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neumora Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Neumora Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or NMRA?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Neumora Therapeutics, Inc. quarterly revenues of --. Nautilus Biotechnology, Inc.'s net income of -$13.8M is higher than Neumora Therapeutics, Inc.'s net income of -$56.8M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Neumora Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus -- for Neumora Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M
-
Which has Higher Returns NAUT or PROK?
ProKidney Corp. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -18156.44%. Nautilus Biotechnology, Inc.'s return on equity of -32.41% beat ProKidney Corp.'s return on equity of -43.81%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M PROKProKidney Corp.-544% -$0.14 $304.8M -
What do Analysts Say About NAUT or PROK?
Nautilus Biotechnology, Inc. has a consensus price target of $4.00, signalling upside risk potential of 21.03%. On the other hand ProKidney Corp. has an analysts' consensus of $6.25 which suggests that it could grow by 228.95%. Given that ProKidney Corp. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe ProKidney Corp. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 PROKProKidney Corp.4 2 0 -
Is NAUT or PROK More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProKidney Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAUT or PROK?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. ProKidney Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or PROK?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than ProKidney Corp. quarterly revenues of $225K. Nautilus Biotechnology, Inc.'s net income of -$13.8M is higher than ProKidney Corp.'s net income of -$40.9M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while ProKidney Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 284.65x for ProKidney Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M PROKProKidney Corp.284.65x -- $225K -$40.9M
-
Which has Higher Returns NAUT or PYXS?
Pyxis Oncology, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -164.03%. Nautilus Biotechnology, Inc.'s return on equity of -32.41% beat Pyxis Oncology, Inc.'s return on equity of -91.8%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M PYXSPyxis Oncology, Inc.52.12% -$0.29 $72.1M -
What do Analysts Say About NAUT or PYXS?
Nautilus Biotechnology, Inc. has a consensus price target of $4.00, signalling upside risk potential of 21.03%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $6.88 which suggests that it could grow by 364.53%. Given that Pyxis Oncology, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 PYXSPyxis Oncology, Inc.7 1 0 -
Is NAUT or PYXS More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAUT or PYXS?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or PYXS?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than Pyxis Oncology, Inc. quarterly revenues of $11M. Nautilus Biotechnology, Inc.'s net income of -$13.8M is higher than Pyxis Oncology, Inc.'s net income of -$18.1M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 6.63x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M PYXSPyxis Oncology, Inc.6.63x -- $11M -$18.1M
-
Which has Higher Returns NAUT or SIGA?
SIGA Technologies, Inc. has a net margin of -- compared to Nautilus Biotechnology, Inc.'s net margin of -143.11%. Nautilus Biotechnology, Inc.'s return on equity of -32.41% beat SIGA Technologies, Inc.'s return on equity of 11.15%.
Company Gross Margin Earnings Per Share Invested Capital NAUTNautilus Biotechnology, Inc.-- -$0.11 $187M SIGASIGA Technologies, Inc.21.2% -$0.08 $199.6M -
What do Analysts Say About NAUT or SIGA?
Nautilus Biotechnology, Inc. has a consensus price target of $4.00, signalling upside risk potential of 21.03%. On the other hand SIGA Technologies, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nautilus Biotechnology, Inc. has higher upside potential than SIGA Technologies, Inc., analysts believe Nautilus Biotechnology, Inc. is more attractive than SIGA Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAUTNautilus Biotechnology, Inc.2 0 0 SIGASIGA Technologies, Inc.0 0 0 -
Is NAUT or SIGA More Risky?
Nautilus Biotechnology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SIGA Technologies, Inc. has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.923%.
-
Which is a Better Dividend Stock NAUT or SIGA?
Nautilus Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Nautilus Biotechnology, Inc. pays -- of its earnings as a dividend. SIGA Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAUT or SIGA?
Nautilus Biotechnology, Inc. quarterly revenues are --, which are smaller than SIGA Technologies, Inc. quarterly revenues of $3.8M. Nautilus Biotechnology, Inc.'s net income of -$13.8M is lower than SIGA Technologies, Inc.'s net income of -$5.4M. Notably, Nautilus Biotechnology, Inc.'s price-to-earnings ratio is -- while SIGA Technologies, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nautilus Biotechnology, Inc. is -- versus 4.03x for SIGA Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAUTNautilus Biotechnology, Inc.-- -- -- -$13.8M SIGASIGA Technologies, Inc.4.03x 16.41x $3.8M -$5.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
